Måns Agrup

1.2k total citations · 1 hit paper
15 papers, 759 citations indexed

About

Måns Agrup is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Neurology. According to data from OpenAlex, Måns Agrup has authored 15 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Genetics and 5 papers in Neurology. Recurrent topics in Måns Agrup's work include Prostate Cancer Diagnosis and Treatment (5 papers), Glioma Diagnosis and Treatment (5 papers) and Neuroblastoma Research and Treatments (5 papers). Måns Agrup is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (5 papers), Glioma Diagnosis and Treatment (5 papers) and Neuroblastoma Research and Treatments (5 papers). Måns Agrup collaborates with scholars based in Sweden and Denmark. Måns Agrup's co-authors include Per Nilsson, Adalsteinn Gunnlaugsson, Lars Franzén, Björn Tavelin, Per Fransson, Jon Kindblom, Anders Widmark, M. Seke, Elisabeth Kjellén and Magnus Lagerlund and has published in prestigious journals such as The Lancet, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Måns Agrup

12 papers receiving 754 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

2019 559 citations Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet profile →

Peers

Countries citing papers authored by Måns Agrup

Since Specialization

Citations

This map shows the geographic impact of Måns Agrup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Måns Agrup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Måns Agrup more than expected).

Fields of papers citing papers by Måns Agrup

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Måns Agrup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Måns Agrup. The network helps show where Måns Agrup may publish in the future.

Co-authorship network of co-authors of Måns Agrup

This figure shows the co-authorship network connecting the top 25 collaborators of Måns Agrup. A scholar is included among the top collaborators of Måns Agrup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Måns Agrup. Måns Agrup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial 2026 ·The Lancet Oncology ·P. Nilsson, Adalsteinn Gunnlaugsson, L. Beckman, Anders Widmark, (unknown), (unknown), Magnus Lagerlund, (unknown), (unknown), Kirsten Björnlinger, Claes Ginman, (unknown), Måns Agrup, (unknown), (unknown), (unknown), (unknown), (unknown), Camilla Thellenberg Karlsson	0
2	Reirradiation and Re-reirradiation of Pediatric Midline Gliomas 2025 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Monica Nilsson, (unknown), (unknown), (unknown), Måns Agrup, (unknown), (unknown), (unknown)	1
3	Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study 2025 ·Journal of Neuro-Oncology ·(unknown), Måns Agrup, (unknown), (unknown), Jacob Engellau, Ingrid Kristensen, (unknown), (unknown), Martin Nilsson, (unknown), (unknown), (unknown)	0
4	Comparative proton and photon treatment plans in children treated for neuroblastoma 2025 ·Acta Oncologica ·(unknown), Ingrid Kristensen, Martin Nilsson, Jacob Engellau, (unknown), (unknown), Måns Agrup, (unknown), (unknown), (unknown)	0
5	4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321) 2025 ·Radiotherapy and Oncology ·Per Nilsson, Adalsteinn Gunnlaugsson, L. Beckman, Anders Widmark, Per Fransson, Morten Høyer, Magnus Lagerlund, Jon Kindblom, Bengt Johansson, Kirsten Björnlinger, Claes Ginman, (unknown), Måns Agrup, Elisabeth Kjellén, Björn Zackrisson, Harald Anderson, Björn Tavelin, Lars Franzén, Camilla Thellenberg Karlsson	1
6	Reirradiation in Paediatric Tumours of the Central Nervous System: Outcome and Side Effects After Implementing National Guidelines 2024 ·Clinical Oncology ·(unknown), Matias Nilsson, Jacob Engellau, Ingrid Kristensen, (unknown), (unknown), Måns Agrup, (unknown), Ulla Martinsson, (unknown), (unknown), (unknown)	1
7	Re-irradiation in Paediatric Tumours of the Central Nervous System: National Guidelines from the Swedish Workgroup of Paediatric Radiotherapy 2023 ·Clinical Oncology ·(unknown), (unknown), (unknown), Martin Nilsson, Måns Agrup, (unknown), (unknown), Ulla Martinsson, Ingrid Kristensen, Jacob Engellau	4
8	Complications after proton radiotherapy in children, focusing on severe late complications. A complete Swedish cohort 2008–2019 2023 ·Acta Oncologica ·Ulla Martinsson, (unknown), Petra Witt Nyström, (unknown), (unknown), Måns Agrup, (unknown), (unknown), Jacob Engellau, Martin Nilsson, Ulf Isacsson, Ingrid Kristensen, (unknown)	4
9	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial 2021 ·The Lancet Oncology ·Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, L. Beckman, Björn Tavelin, David Norman, Camilla Thellenberg‐Karlsson, Morten Høyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, M. Seke, Måns Agrup, Björn Zackrisson, Elisabeth Kjellén, Lars Franzén, Anders Widmark	93
10	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial breakdown → 2019 ·The Lancet ·Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman, Camilla Thellenberg‐Karlsson, Morten Høyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, M. Seke, Måns Agrup, Per Fransson, Björn Tavelin, David Norman, Björn Zackrisson, Harald Anderson, Elisabeth Kjellén, Lars Franzén, Per Nilsson	559
11	OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial 2018 ·Radiotherapy and Oncology ·Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman, Camilla Thellenberg‐Karlsson, Morten Høyer, Magnus Lagerlund, Per Fransson, Björn Tavelin, David Norman, Jon Kindblom, Claes Ginman, Bengt Johansson, M. Seke, (unknown), Måns Agrup, Elisabeth Kjellén, Lars Franzén, Peter M. Nilsson	14
12	A dose based approach for evaluation of inter-observer variations in target delineation 2017 ·Technical Innovations & Patient Support in Radiation Oncology ·Ingrid Kristensen, Kristina Nilsson, Måns Agrup, (unknown), (unknown), (unknown), (unknown), Tommy Knöös, Per Nilsson	3
13	Assessment of volume segmentation in radiotherapy of adolescents; a treatment planning study by the Swedish Workgroup for Paediatric Radiotherapy 2013 ·Acta Oncologica ·Ingrid Kristensen, Måns Agrup, Per Bergström, Jacob Engellau, (unknown), Ulla Martinsson, Kristina Nilsson, (unknown), Jack Lindh, Per Nilsson	4
14	Telemedicine as a tool for sharing competence in paediatric radiotherapy – Implementation and initial experiences from a Swedish project 2008 ·Acta Oncologica ·Ingrid Kristensen, Jack Lindh, Per Nilsson, Måns Agrup, Per Bergström, Thomas Björk‐Eriksson, Jacob Engellau, (unknown), Beatrice Malmer, Ulla Martinsson, Mikael Karlsson	16
15	C-erbB-2 overexpression and survival in early onset breast cancer 2000 ·Breast Cancer Research and Treatment ·Måns Agrup, (unknown), Karen Ege Olsen, Sten Wingren	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact